pCGS Rotta/Dona canon EULAR · generic sulfate possible alternative · HCl NOT recommended (no equivalent evidence).
Patented crystalline glucosamine sulfate
Best for
Ideal use: mild-moderate knee OA · structure-modifying · EULAR canon.
Advantages
Canon RCT form (Reginster, Pavelka, Bruyere). EULAR 2024 Grade A strong recommendation. HPLC standardization + validated bioequivalence. Stable crystalline.
Disadvantages
Expensive (~€30-45/month) vs generics. Only OTC Spain as Dona Pharma · USA only prescription Rotta.
Same active ingredient · variable formulation
Best for
Ideal use: budget · patients who prefer non-pharmacy · validate brand with analysis.
Advantages
Affordable (~€15-25/month). Same molecule. Acceptable per ESCEO if equivalent bioequivalence formulation.
Disadvantages
Variable RCT results · NOT equivalent to pCGS Rotta in all trials. Heterogeneous quality.
Majority USA form · GAIT trial
Best for
Use NOT recommended (limited): only if pCGS unavailable · insufficient evidence.
Advantages
Higher concentration 74% (vs 59% sulfate). Affordable.
Disadvantages
GAIT 2006 NEGATIVE (n=1,583) WOMAC no improvement vs placebo. Mihalko 2024 head-to-head pCGS superior. NOT recommended EULAR.
Ideal use: mild-moderate knee OA · structure-modifying · EULAR canon.
Ideal use: budget · patients who prefer non-pharmacy · validate brand with analysis.
Use NOT recommended (limited): only if pCGS unavailable · insufficient evidence.
pCGS Rotta/Dona canon EULAR · generic sulfate possible alternative · HCl NOT recommended (no equivalent evidence).